8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial
In a triple-blind, placebo-controlled crossover trial, 51 hypertensive patients received either celery seed capsules (1.34 g extract daily) or placebo for 4 weeks alongside usual medications. Celery seed extract was safe, reduced blood pressure, and decreased FBS from 108.53 to 97.96 mg/dL (p < 0.01). Significant reductions were seen in BUN (3.43 mg/dL), SCr (0.075 mg/dL), SGPT (4.08 U/L), SGOT (3.03 U/L), TC (16.37 mg/dL), TG (16.22 mg/dL), and LDL (11.84 mg/dL), along with an increase in HDL of 2.52 mg/dL (all p < 0.05 or p < 0.001). No significant changes were found in blood cells or serum electrolytes; the study was limited by a small sample size.
Shayani Rad M, Moohebati M, MohammadEbrahimi S, et al. Inflammopharmacology, 2022. PMID 35536382
2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial
A randomized, triple-blind, placebo-controlled crossover trial evaluated the effect of 4 celery seed extract capsules (1.34 g/day) versus placebo taken daily for 4 weeks in 52 hypertensive patients. In the celery group, systolic blood pressure decreased from 141.2 ± 5.91 to 130.0 ± 4.38 mmHg (p < .001) and diastolic blood pressure decreased from 92.2 ± 5.74 to 84.2 ± 4.87 mmHg (p < .001). Mean arterial blood pressure also changed from 108.5 ± 5.76 to 99.5 ± 4.66 mmHg (p < .001), and pulse pressure decreased from 49.0 ± 6.21 to 45.8 ± 6.01 mmHg (p < .01), whereas no significant changes occurred with placebo (p > .05). No significant side effects were reported in the celery group compared to placebo (p > .05).
Shayani Rad M, Moohebati M, Mohajeri SA Phytother Res, 2022. PMID 35624525
2022 / Uncontrolled interventional program evaluation
Participants enrolled in a 15-day Jumpstart program were instructed to consume an Esselstyn-compliant, whole-food plant-based diet of vegetables, fruits, whole grains, and legumes. Among 389 participants, average weight loss was 5.8 pounds (7.3 for BMI >30), systolic blood pressure dropped by 6.8 points (16.8 for baseline >140), cholesterol decreased by 26 points (44 for baseline >200), LDL dropped by 19 points (33 for baseline >100), and fasting blood sugar fell by 5.1 points (28.4 for those starting in the diabetic range). All reported comparisons achieved statistical significance (P < .005 for fasting blood sugar and P < .001 for all others).
Friedman SM, Barnett CH, Franki R, et al. Am J Lifestyle Med, 2022. PMID 35706593
2021 / Randomized, double-blind, crossover trial
Sixteen overweight older adults consumed a high-fat high-energy meal with 250 mL of either anthocyanin-rich Queen Garnet Plum juice or control apricot juice in a randomized crossover trial. Compared to control, the anthocyanin arm had higher 2-hour postprandial flow-mediated dilatation (+1.14%, P = 0.019) and higher microvascular post-occlusive reactive hyperaemia (+0.10 perfusion units per mmHg, P = 0.049). C-reactive protein was lower at 4 hours postprandially in the anthocyanin arm (1.80 mg/L) compared with control (2.30 mg/L, P = 0.026). No significant postprandial differences were found for blood pressure, lipids, oxidative metabolites, or other inflammatory markers.
do Rosario VA, Chang C, Spencer J, et al. Clin Nutr, 2021. PMID 33071012
2021 / Multicenter randomized controlled trial
The OMEMI trial evaluated whether adding 1.8 g of n-3 PUFA (930 mg EPA and 660 mg DHA) daily versus corn oil placebo to standard of care reduced cardiovascular events over 2 years in patients aged 70 to 82 years with recent AMI. Among 1014 analyzed patients, the primary composite endpoint occurred in 21.4% (108/505) of the n-3 PUFA group and 20.0% (102/509) of the placebo group (HR 1.08 [95% CI, 0.82-1.41]; P=0.60). New atrial fibrillation occurred in 7.2% vs 4.0% (HR 1.84 [95% CI, 0.98-3.45]; P=0.06), and major bleeding occurred in 10.7% vs 11.0% (P=0.87). The authors concluded they could not detect a reduction in clinical events with 1.8 g n-3 PUFAs daily for 2 years in this population.
Kalstad AA, Myhre PL, Laake K, et al. Circulation, 2021. PMID 33191772
2021 / Randomized open-label controlled trial
A 12-week randomized trial examined the effects of Melissa officinalis (MO) tea (2 g dried leaves twice daily plus lifestyle recommendations) compared to lifestyle recommendations alone in 60 patients with PVCs. Patients receiving MO tea had significantly lower adjusted mean 24-hour premature ventricular beats (2142.39 vs. 3126.05; P = .017). They also showed significantly lower adjusted means for triglycerides (144.75 vs. 174.27 mg/dL), total cholesterol (155.35 vs. 171.99 mg/dL), and fasting blood sugar (90.85 vs. 99.84 mg/dL; P <= .042). The intervention did not significantly affect LDL-C or HDL-C levels.
Kheirkhah J, Ghorbani Z, Salari A, et al. Int J Clin Pract, 2021. PMID 34309987
2020 / Randomized, placebo-controlled, 2x2 factorial trial and meta-analyses
The VITAL trial evaluated daily vitamin D3 (2000 IU) and marine omega-3 fatty acids (1 g) over a median of 5.3 years in 25,871 older U.S. adults. Vitamin D did not significantly reduce total invasive cancer incidence (HR = 0.96 [95% CI 0.88-1.06]), major CVD events (HR = 0.97 [0.85-1.12]), or all-cause mortality (HR = 0.99 [0.87-1.12]). However, it showed a signal for reduced total cancer mortality (HR = 0.83 [0.67-1.02]), which was significant when excluding the first year (HR = 0.79 [0.63-0.99]) or first 2 years (HR = 0.75 [0.59-0.96]) of follow-up. Updated meta-analyses including VITAL and other trials indicated a significant reduction in cancer mortality, but not cancer incidence or CVD endpoints.
Manson JE, Bassuk SS, Buring JE, et al. J Steroid Biochem Mol Biol, 2020. PMID 31733345
2020 / Randomized controlled trial
The IRONIC trial randomized 158 patients with mild-to-severe intermittent claudication to revascularization plus medical therapy and structured exercise, or medical therapy and structured exercise alone. At 5 years, no significant intergroup differences were observed for SF-36 scores, except for the role emotional domain which favored the nonrevascularization group (P=0.007). There were also no differences in VascuQoL scores or treadmill walking distances, while revascularization incurred nearly double the cost per patient ($13,098 vs $6,965, P=0.02).
Djerf H, Millinger J, Falkenberg M, et al. Circ Cardiovasc Interv, 2020. PMID 31937137
2020 / Randomized crossover trial
Fifty healthy adults completed a randomized crossover trial comparing four weeks of daily non-fried potato side dishes against refined grains. Fasting plasma glucose did not differ between treatments (-0.05 mmol/l, 95% CI -0.14 to 0.04, P = 0.15), and no differences emerged for cardiometabolic endpoints. Potato consumption resulted in higher Healthy Eating Index-2015 scores (difference 3.5, 95% CI 0.6 to 6.4), potassium (547 mg, 95% CI 331 to 764), and dietary fiber (2.4 g, 95% CI 0.6 to 4.2).
Johnston EA, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 31964428
2020 / Cluster randomized trial
The Salt Substitute and Stroke Study is an ongoing 5-year cluster randomized trial evaluating potassium-enriched salt substitute versus usual salt in 20,996 individuals across 600 Chinese villages. Intermediate markers assessed over 3 years showed mean differences between the intervention and control groups of -0.32 g (95% CI: -0.68 to 0.05) for 24-hour urinary sodium, +0.77 g (+0.60 to +0.93) for 24-hour urinary potassium, and -2.65 mmHg (-4.32 to -0.97) for systolic blood pressure. Diastolic blood pressure difference was +0.30 mmHg (-0.72 to +1.32). Salt substitute use was 97.5% in the intervention group versus 4.2% in controls, and the overall annual fatal and non-fatal stroke rate across the first 2 years was 3.2%.
Huang L, Tian M, Yu J, et al. Am Heart J, 2020. PMID 31986290
2020 / Randomized crossover trial
In a randomized crossover trial, 12 healthy adults ate a high-fat meal followed by 4 hours of uninterrupted sitting or sitting interrupted every hour with 5 minutes of stair climbing. Plasma triglycerides and glucose increased after the meal and returned to baseline at the end of both trials. Brachial artery flow-mediated dilation decreased with uninterrupted sitting (9.65 ± 2.63% to 7.84 ± 2.36%) but not with interrupted sitting (9.41 ± 2.61% to 10.34 ± 3.30%, p = 0.009 for interaction). Compared with uninterrupted sitting, the interrupted trial improved popliteal blood flow and shear rate (p = 0.004 and p = 0.008 for interaction, respectively).
Cho MJ, Bunsawat K, Kim HJ, et al. Eur J Appl Physiol, 2020. PMID 32065258
2020 / Cluster randomized trial
A cluster randomized trial in 2,376 participants in Peru evaluated replacing household salt with a 75% sodium chloride and 25% potassium chloride substitute. The intervention reduced systolic blood pressure by 1.29 mm Hg (95% CI -2.17 to -0.41) and diastolic blood pressure by 0.76 mm Hg (95% CI -1.39 to -0.13). Among participants normotensive at baseline, salt substitution was linked to a 51% lower risk of developing hypertension (95% CI 29% to 66%).
Bernabe-Ortiz A, Sal Y Rosas VG, Ponce-Lucero V, et al. Nat Med, 2020. PMID 32066973
2020 / Phase II double-blind randomized placebo-controlled trial
In a 6-month trial, 44 participants with peripheral artery disease were randomized to consume a daily cocoa beverage (15 g cocoa, 75 mg epicatechin) or a placebo. Adjusting for smoking, race, and BMI, cocoa improved 6-minute walk distance by 42.6 m (90% CI, +22.2 to +∞; P=0.005) at 2.5 hours after a final beverage, and by 18.0 m (90% CI, -1.7 to +∞; P=0.12) at 24 hours post-beverage compared to placebo. Calf muscle biopsies showed cocoa improved mitochondrial cytochrome c oxidase activity (P=0.013), increased capillary density (P=0.014), improved perfusion (P=0.098), and reduced central nuclei (P=0.033).
McDermott MM, Criqui MH, Domanchuk K, et al. Circ Res, 2020. PMID 32078436
2020 / Two-period randomized crossover trial
In a randomized crossover trial, 55 adults with elevated BMI and cardiometabolic risk consumed 3/4 cup/day of mixed dried fruits (plums, figs, dates, raisins) or an isocaloric, carbohydrate-matched control snack for 4 weeks. Lipid and lipoprotein concentrations did not differ between conditions, though dried fruit increased LDL-cholesterol from baseline (0.10 mmol/l, 95% CI 0.01, 0.20). Compared with control, dried fruit increased mean fasting glucose (0.08 mmol/l, 95% CI 0.005, 0.16; P = 0.038), while vascular outcomes, fasting insulin, and C-reactive protein did not differ. Mean weight changes did not differ between groups (P = 0.55), but tended to increase in both.
Sullivan VK, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 32513313
2020 / Randomized crossover trial
In the SWAP-MEAT crossover trial, 36 healthy adults consumed ≥2 servings/day of plant-based alternative meat versus animal meat for 8 weeks each with no washout period. Overall mean ± SEM TMAO concentrations were lower during the plant phase (2.7 ± 0.3 vs. 4.7 ± 0.9 µM, P = 0.012), though a significant order effect occurred; TMAO was significantly lower only in participants receiving plant meat second. LDL-cholesterol concentrations (109.9 ± 4.5 vs. 120.7 ± 4.5 mg/dL, P = 0.002) and body weight (78.7 ± 3.0 vs. 79.6 ± 3.0 kg, P < 0.001) were also significantly lower during the plant-based phase.
Crimarco A, Springfield S, Petlura C, et al. Am J Clin Nutr, 2020. PMID 32780794
2020 / Parallel-group, double-blind, randomized controlled trial
A parallel-group, double-blind trial randomized 159 patients with CKD stage 3b or 4 to receive 400 μg oral vitamin K2 (n=80) or matching placebo (n=79) once daily for 1 year. The study found no differences between groups in carotid-femoral pulse wave velocity at 12 months, augmentation index at 12 months, blood pressure, B-type natriuretic peptide, or physical function. Furthermore, an updated meta-analysis of trials conducted by the authors showed no effect of vitamin K supplementation on vascular stiffness or vascular calcification measures.
Witham MD, Lees JS, White M, et al. J Am Soc Nephrol, 2020. PMID 32817311
2020 / Double-blind, randomized, multicenter trial
A total of 13,078 statin-treated patients at high cardiovascular risk were randomized to receive 4 g/d of an omega-3 carboxylic acid formulation (EPA/DHA) or corn oil. The trial was prematurely halted for low probability of clinical benefit. The primary composite endpoint occurred in 12.0% of omega-3 CA patients versus 12.2% of corn oil patients (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A higher rate of gastrointestinal adverse events occurred in the omega-3 group (24.7%) compared to the corn oil group (14.7%).
Nicholls SJ, Lincoff AM, Garcia M, et al. JAMA, 2020. PMID 33190147
2019 / Double-blind randomized controlled trial
In the double-blinded randomized controlled FLAX-PAD trial, PAD patients consumed a diet supplemented with either 30 g of milled flaxseed or placebo daily for 1 year. At baseline, cardiac arrhythmias were present in 48% of the flaxseed group and 32% of the placebo group. After 1 year, cardiac arrhythmias decreased by 2% in the flaxseed group and increased by 12% in the placebo group, which was not statistically significant (P > 0.05). Electrocardiographic variables did not change in either group, and improvements in initial and absolute claudication distances did not show a statistically significant intergroup difference.
Rodriguez-Leyva D, Rodriguez-Portelles A, Weighell W, et al. Can J Physiol Pharmacol, 2019. PMID 30308127
2019 / Multicenter, randomized, double-blind, placebo-controlled trial
A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).
Bhatt DL, Steg PG, Miller M, et al. N Engl J Med, 2019. PMID 30415628
2019 / Randomized, placebo-controlled trial (two-by-two factorial)
A randomized, placebo-controlled trial tested vitamin D3 (2000 IU/day) versus placebo for the prevention of cancer and cardiovascular disease over a median follow-up of 5.3 years in 25,871 participants. Vitamin D was not associated with a lower risk of invasive cancer (HR 0.96; 95% CI, 0.88 to 1.06; P=0.47) or major cardiovascular events (HR 0.97; 95% CI, 0.85 to 1.12; P=0.69). Secondary endpoints, including death from cancer (HR 0.83; 95% CI, 0.67 to 1.02) and death from cardiovascular causes (HR 1.11; 95% CI, 0.88 to 1.40), also showed no significant differences, and no excess risks of hypercalcemia or other adverse events were identified.
Manson JE, Cook NR, Lee IM, et al. N Engl J Med, 2019. PMID 30415629
2019 / Randomized, placebo-controlled, 2x2 factorial trial
In the VITAL trial, 25,871 participants were randomized to 1 g per day of marine n-3 fatty acids or placebo (alongside vitamin D3 in a 2x2 factorial design) with a median follow-up of 5.3 years. Marine n-3 fatty acid supplementation did not significantly lower major cardiovascular events (HR, 0.92; 95% CI, 0.80 to 1.06; P=0.24) or invasive cancer (HR, 1.03; 95% CI, 0.93 to 1.13; P=0.56). For secondary endpoints, total myocardial infarction was lower in the n-3 group (HR, 0.72; 95% CI, 0.59 to 0.90), but stroke, cancer death, and all-cause death showed no significant differences. No excess risks of bleeding or other serious adverse events were observed.
Manson JE, Cook NR, Lee IM, et al. N Engl J Med, 2019. PMID 30415637
2019 / Controlled trial
In a controlled trial, 49 strict vegan participants took oral creatine monohydrate (5 g daily, n = 31) or placebo (n = 18) for three weeks. Creatine intake normalized homocysteine levels in all participants and increased blood folic acid concentrations. Supplementation also increased baseline skin capillary density and endothelium-dependent capillary recruitment, while enhancing microvascular vasodilation specifically in participants with elevated baseline homocysteine.
Van Bavel D, de Moraes R, Tibirica E Fundam Clin Pharmacol, 2019. PMID 30506745
2019 / Clinical trial
Researchers evaluated isotope-labeled l-carnitine and gamma-butyrobetaine metabolism in 40 omnivores and 32 vegans or vegetarians. Following oral d3-l-carnitine, omnivores generated over 20-fold more d3-TMAO than vegans or vegetarians (P = 0.001), despite comparable fasting plasma carnitine levels. Gut bacteria transformed carnitine into gamma-butyrobetaine in both dietary groups, but conversion of gamma-butyrobetaine to TMA was induced by chronic carnitine intake and omnivorous habits.
Koeth RA, Lam-Galvez BR, Kirsop J, et al. J Clin Invest, 2019. PMID 30530985
2019 / Single-blinded randomized controlled trial
In a 12-week single-blinded trial, 77 constipated patients with type 2 diabetes received cookies containing 10 g flaxseed, 10 g psyllium, or placebo twice daily. Compared to placebo, both flaxseed and psyllium groups showed significant improvements from baseline in constipation symptoms (P = 0.002), stool consistency (P < 0.001), weight (P < 0.001), BMI (P < 0.001), fasting plasma glucose (P = 0.004), cholesterol (P = 0.010), LDL cholesterol (P = 0.031), and cholesterol/HDL cholesterol ratio (P = 0.019). Flaxseed appeared superior to psyllium for improving these markers, and no adverse effects were observed.
Soltanian N, Janghorbani M Clin Nutr ESPEN, 2019. PMID 30661699